Noronha V, Krishna M V, Patil V, Joshi A, Banavali S D, Prabhash K
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
Indian J Cancer. 2013 Apr-Jun;50(2):142-8. doi: 10.4103/0019-509X.117027.
Cytotoxic antiproliferative chemotherapeutic agents are the mainstay of treatment in cancers. Chemotherapy is usually administered every 2-3 weeks. Along with acute toxicity and long-term effects of cumulative doses, this strategy potentially allows regrowth of the tumor in the interval period and leads to the emergence of resistant populations of tumor cells. Moreover, even with intense chemotherapy, the outcome is stagnating for most of the tumors. There has been recent interest in the use of chemotherapy in fractionated doses which is far below the maximum tolerated dose. This is called metronomic scheduling of chemotherapy. Here, we review the biology and evidence for metronomic chemotherapy.
细胞毒性抗增殖化疗药物是癌症治疗的主要手段。化疗通常每2至3周进行一次。除了急性毒性和累积剂量的长期影响外，这种策略可能会使肿瘤在间隔期重新生长，并导致肿瘤细胞耐药群体的出现。此外，即使进行强化化疗，大多数肿瘤的治疗效果仍停滞不前。最近人们对使用远低于最大耐受剂量的分次剂量化疗产生了兴趣。这被称为节拍式化疗方案。在此，我们综述节拍式化疗的生物学原理和证据。
